Global Cancer Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Cancer Immunotherapy Market is presumed to reach the market size of nearly USD 236.93 BN by 2030 from USD 117.09 BN in 2022 with a CAGR of 9.21% under the study period 2023 - 2030.

Cancer immunotherapy, or immuno-oncology, refers to a treatment approach that utilizes the remarkable capabilities of the body's immune system to combat cancer. The immune system serves as the body's inherent defence mechanism against various diseases, including cancer. It consists of various cells, tissues, and organs that work together to identify and destroy abnormal cells, including cancer cells.

MARKET DYNAMICS:

The cancer immunotherapy market is witnessing significant growth due to several key factors. First, there is a rising incidence of cancer worldwide, driving the demand for effective treatment options. Immunotherapy, with its potential to target various types of cancers, has emerged as a promising solution. Second, the favourable clinical outcomes of immunotherapy, including improved survival rates and long-term outcomes, have boosted its adoption. Third, advancements in immunotherapy techniques, such as the discovery of novel targets and the development of combination therapies, have enhanced treatment efficacy. Government initiatives, funding support, and streamlined regulatory processes have also played a crucial role in fueling market growth. Furthermore, collaborations and partnerships between pharmaceutical companies and research institutions have accelerated innovation in the field. Increased investment and market competition have resulted in the development of diverse immunotherapeutic agents. The personalized medicine approach, where treatments are tailored to individual patients, has further propelled the market. Additionally, expanded indications and approvals of immunotherapeutic agents have widened the potential patient population. Overall, these factors, coupled with ongoing research and technological advancements, are expected to drive continued growth in the cancer immunotherapy market.

The research covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cancer immunotherapy. The growth and trends of cancer immunotherapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cancer immunotherapy market provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Monoclonal Antibodies
Immunomodulators
Oncolytic Viral Therapies & Cancer Vaccines

By Application

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head & Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By End Use

Hospitals & Clinics
Cancer Research Centers
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cancer Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cancer immunotherapy market include Pfizer Inc, AstraZeneca, Merck & Co., Inc; F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Lilly, Johnson & Johnson Services, Inc; Immunocore, Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized as per your need.

Product Code: VMR112111378

1 . PREFACE

1.1. Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CANCER IMMUNOTHERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By End Use
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY PRODUCT

5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 Monoclonal Antibodies Historic and Forecast Sales by Regions
5.5 Immunomodulators Historic and Forecast Sales by Regions
5.6 Oncolytic Viral Therapies & Cancer Vaccines Historic and Forecast Sales by Regions

6 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Lung Cancer Historic and Forecast Sales by Regions
6.5 Breast Cancer Historic and Forecast Sales by Regions
6.6 Colorectal Cancer Historic and Forecast Sales by Regions
6.7 Melanoma Historic and Forecast Sales by Regions
6.8 Prostate Cancer Historic and Forecast Sales by Regions
6.9 Head & Neck Cancer Historic and Forecast Sales by Regions
6.10. Ovarian Cancer Historic and Forecast Sales by Regions
6.11 Pancreatic Cancer Historic and Forecast Sales by Regions
6.12 Others Historic and Forecast Sales by Regions

7 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacy Historic and Forecast Sales by Regions
7.5 Retail Pharmacy Historic and Forecast Sales by Regions
7.6 Online Pharmacy Historic and Forecast Sales by Regions

8 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY END USE

8.1 Overview by End Use
8.2 Historical and Forecast Data
8.3 Analysis by End Use
8.4 Hospitals & Clinics Historic and Forecast Sales by Regions
8.5 Cancer Research Centers Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Data Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Data Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Data Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Data Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Data Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CANCER IMMUNOTHERAPY COMPANIES

10.1. Cancer Immunotherapy Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF CANCER IMMUNOTHERAPY INDUSTRY

11.1. Company Share Analysis
11.2. Market Concentration Rate
11.3. Pfizer Inc
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. AstraZeneca
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Merck & Co. Inc
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. F. Hoffmann-La Roche Ltd
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Bristol-Myers Squibb Company
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Novartis AG
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Lilly
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Johnson & Johnson Services Inc
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Immunocore Ltd
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies